secwatch.observer — SEC 8-K summary
======================================

Issuer:     KYNTRA BIO, INC. (KYNB)
CIK:        0000921299
Form:       8-K
Filed at:   2022-06-08T23:59:59+00:00
Accession:  0000950170-22-011324
Event type: leadership
Sentiment:  neutral
Materiality: 0.35
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Director Thomas F. Kearns to resign from FibroGen Board effective June 16, 2022
-------------------------------------------------------------------------------

- Thomas F. Kearns, Jr. notified resignation from the Board effective June 16, 2022.
- Resignation not due to any disagreement with FibroGen's operations, policies or practices.
- Kearns served since 1996, including as Chair, Lead Independent Director, and committee chairs.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/921299/000095017022011324/0000950170-22-011324-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/921299/000095017022011324/fgen-20220605.htm
  HTML page:      https://secwatch.observer/filing/0000950170-22-011324

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer